CliffBio
small molecule

REZZAYO

REZAFUNGIN ACETATE

Loss of exclusivityJuly 2038latest FDA-listed patent expiry
CompanyMUNDIPHARMA GMBH

Drug detail

Brand nameREZZAYO
Active ingredientREZAFUNGIN ACETATE
StrengthEQ 200MG BASE/VIAL
Dosage formPOWDER
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalMarch 2023
Marketing statusRX

Listed patents

PatentExpiresType
11197909July 2038substance, product
11819533July 2038substance, product
11712459March 2037product
8722619May 2036substance, product
9526835March 2033substance, product
10702573March 2033substance, product
11654196March 2032substance, product

Regulatory exclusivity

CodeExpires
GAINMarch 2035
GAINMarch 2033
ODE-426March 2030
NCEMarch 2028

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

REZZAYO patent cliff — loss of exclusivity July 2038 | CliffBio